Pay in 4 interest-free payments of $5.26 Learn more
Ships within 48 hours · Estimated delivery Oct 24 - Oct 29
Some clients benefit from weekly or bi-weekly sessions , while others prefer monthly treatments for maintenance and wellness support
You know exactly what's in the vial
This triple mechanism does not treat a disease endpoint it reprograms the metabolic environment in which obesity, type 2 diabetes, MASH, cardiovascular disease, and multiple chronic conditions emerge and progress
It may be easier to follow than medicines taken several times a day
Lynparza (olaparib) Disease area(s): Oncology Manufacturer(s): AstraZeneca/Merck 2024 Sales (USD): $4.98 billion Why it sold so well: AstraZenecas Lynparza delivered a strong sales performance in 2024, with product revenues reaching $3.67 billion, marking a 22% increase at constant exchange rates compared to the previous year
Saxenda European Medicines Agency medicine overview
US$ 25.12
US$ 29.07
US$ 23.78
US$ 23.73
US$ 22.67
US$ 22.54
US$ 24.36
US$ 25.87
US$ 22.76
US$ 20.39
US$ 29.63
US$ 23.96
US$ 28.72
US$ 27.09
US$ 20.50
US$ 27.43
US$ 27.26
